Savara Inc.

SVRA

$5.31

-1.12%

N/A-$0.06

Healthcare

Biotechnology

NASDAQ

Active Trading

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, ...

Recent News of SVRA

Business Wire8/11/2026Neutral

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update. “While we have regulatory applications under review across the U.S., EU, and U.K., the U.S. represents our nearest-term opportunity,” said Matt Pauls, J.D., M.B.A., Chair and Chief Executive Officer, Savara. “Our focus is on the potential l.

Seeking Alpha8/5/2026Neutral

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress. The article assesses SVRA's clinical and regulatory milestones as key investment drivers. Upcoming APAP BLA PDUFA is highlighted as a pivotal near-term catalyst.

Business Wire7/30/2026Neutral

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has a.

Zacks Investment Research7/22/2026Neutral

Here's Why You Should Add Savara Stock to Your Portfolio Now

SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.

The Motley Fool6/27/2026Neutral

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

394,528 shares of Common Stock were sold for about $2.24 million on June 22, 2026, at a weighted average price of around $5.68 per share. This transaction represented 42.40% of the executive's total common stock holdings pre-transaction.

Savara Inc.

Recent News of SVRA

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

Here's Why You Should Add Savara Stock to Your Portfolio Now

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

Here's Why You Should Add Savara Stock to Your Portfolio Now

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

Savara Announces New Employment Inducement Grant

Savara Announces Chief Financial and Administrative Officer Transition

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara: The Rare Disease Funnel Is Becoming A Commercial Asset

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Supply Chain of SVRA

Upstream

Downstream

Proxies

Recent News of SVRA

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

Here's Why You Should Add Savara Stock to Your Portfolio Now

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

Here's Why You Should Add Savara Stock to Your Portfolio Now

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

Savara Announces New Employment Inducement Grant

Savara Announces Chief Financial and Administrative Officer Transition

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara: The Rare Disease Funnel Is Becoming A Commercial Asset

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Supply Chain of SVRA

Upstream

Downstream

Proxies